News
Roche’s Genentech Earmarks $700M for North Carolina Plant as Billion-Dollar US Pledge Hangs in Balance
The commitment is part of Roche’s recently announced $50 billion investment in the U.S., but a company spokesperson said that could change if certain yet-unspecified policies are implemented that could “harm our industry’s ability to operate and innovate in America.
Roche gets to work on US investment plan with reveal of $700M obesity drug plant in North Carolina
About a month after disclosing a $50 billion investment in its U.S. | Roche has earmarked more than $700 million to construct a sprawling new plant for its Genentech unit in Holly Springs, North Carolina.
Genentech plans to invest $700 million in a new facility in Holly Springs, North Carolina, creating 420 jobs and joining the ...
Roche’s Herceptin and Perjeta duo is already part of a well-established standard of care in early-stage HER2-positive breast ...
The committee awarded a grant to Genentech, a Roche subsidiary, to open a 420-worker, drug-manufacturing plant in the ...
Genentech, considered one of the biotech industry’s founding companies, plans to build a $700 million, 700,000-square-foot ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Institut Jules ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback